Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
T4 endonuclease V is a DNA repair enzyme originally derived from the T4 bacteriophage. It specifically targets cyclobutane pyrimidine dimers (CPDs), which are the most prevalent DNA lesions induced by ultraviolet (UV) radiation. The enzyme possesses a dual catalytic mechanism: it acts as a DNA glycosylase, cleaving the glycosidic bond of the 5' pyrimidine of the dimer, followed by an AP-lyase activity that cleaves the phosphodiester bond. In clinical development, the enzyme is typically encapsulated in pH-sensitive liposomes (referred to as T4N5 liposomes) to enable delivery into the cytoplasm and subsequently the nuclei of keratinocytes. It has been primarily investigated as a chemopreventive agent to reduce the incidence of actinic keratosis and non-melanoma skin cancers, particularly in high-risk populations such as patients with xeroderma pigmentosum (XP).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on t4 endonuclease v.